Skip Navigation



Annals of Oncology Advance Access published online on October 25, 2006
Annals of Oncology, doi:10.1093/annonc/mdl370
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/2/269    most recent
mdl370v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kodama, J.
Right arrow Articles by Hiramatsu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kodama, J.
Right arrow Articles by Hiramatsu, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received May 12, 2006
Revised August 23, 2006
Accepted September 6, 2006

original article

Prognostic significance of stromal versican expression in human endometrial cancer

J. Kodama 1 *, Hasengaowa 2, T. Kusumoto 1, N. Seki 1, T. Matsuo 1, Y. Ojima 1, K. Nakamura 1, A. Hongo 1, and Y. Hiramatsu 1

1 Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
2 Department of Obstetrics and Gynecology, Inner Mongolia Agriculture University Hospital, Huhehaote, China

* To whom correspondence should be addressed.
J. Kodama, E-mail: kodama{at}cc.okayama-u.ac.jp


  Abstract

Background: Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in human endometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers.

Patients and methods: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome.

Results: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P < 0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS.

Conclusions: Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.

Keywords: endometrial cancer; prognosis; tumor progression; versican.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. Domenzain-Reyna, D. Hernandez, L. Miquel-Serra, M. J. Docampo, C. Badenas, A. Fabra, and A. Bassols
Structure and Regulation of the Versican Promoter: THE VERSICAN PROMOTER IS REGULATED BY AP-1 AND TCF TRANSCRIPTION FACTORS IN INVASIVE HUMAN MELANOMA CELLS
J. Biol. Chem., May 1, 2009; 284(18): 12306 - 12317.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Soltermann, V. Tischler, S. Arbogast, J. Braun, N. Probst-Hensch, W. Weder, H. Moch, and G. Kristiansen
Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non-Small Cell Lung Cancer
Clin. Cancer Res., November 15, 2008; 14(22): 7430 - 7437.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.